Premium
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc min mice
Author(s) -
Myzak Melinda C.,
Dashwood W. Mohaiza,
Orner Gayle A.,
Ho Emily,
Dashwood Roderick H.
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.05-4785fje
Subject(s) - sulforaphane , in vivo , histone deacetylase , chemistry , carcinogenesis , cancer research , histone , hdac1 , microbiology and biotechnology , biochemistry , biology , genetics , gene
Sulforaphane (SFN) is an isothiocyanate from broccoli that induces phase 2 detoxification enzymes. We recently reported that SFN acts as a histone deacetylase (HDAC) inhibitor in human colon cancer cells in vitro, and the present study sought to extend these findings in vivo. In mice treated with a single oral dose of 10 ümol SFN, there was significant inhibition of HDAC activity in the colonic mucosa after 6 h, and immunoblots revealed a concomitant increase in acetylated histones H3 and H4, which returned to control levels by 48 h. Longer‐term treatment with SFN in the diet resulted in levels of acetylated histones and p21 WAF1 in the ileum, colon, prostate, and peripheral blood mononuclear cells that were elevated compared with controls. Consistent with these findings, SFN suppressed tumor development in Apc min mice, and there was an increase in acetylated histones in the polyps, including acetylated histones specifically associated with the promoter region of the P21 and bax genes. These results provide the first evidence for HDAC inhibition by SFN in vivo and imply that such a mechanism might contribute to the cancer chemoprotective and therapeutic effects of SFN, alone or in combination with other HDAC inhibitors currently undergoing clinical trials.